Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2

Molecular Oncology

Volumn 7, Issue 3, 2013, Pages 484-496

  Li, Likun ^a   Yang, Guang ^a   Ren, Chengzhen ^a   Tanimoto, Ryuta ^a   Hirayama, Takahiro ^a   Wang, Jianxiang ^a   Hawke, David ^a   Kim, Soo Mi ^a   Lee, Ju Seog ^a   Goltsov, Alexei A ^a   Park, Sanghee ^a   Ittmann, Michael M ^b,c   Troncoso, Patricia ^a   Thompson, Timothy C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

AURKA; C Myb; Glioma pathogenesis related protein 1 (GLIPR1); Hsc70; Prostate cancer; TPX2

Indexed keywords

GLIOMA PATHOGENESIS RELATED PROTEIN 1; HEAT SHOCK COGNATE PROTEIN 70; PROTEIN P53; SMALL INTERFERING RNA; SYNAPSIN I; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; GENE DELETION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; ONCOGENE C MYB; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84878110677     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.12.005     Document Type: Article

References (47)

1. Anand S., Penrhyn-Lowe S., Venkitaraman A.R. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003, 3:51-62.
2. Andrews P.D. Aurora kinases: shining lights on the therapeutic horizon?. Oncogene 2005, 24:5005-5015.
3. Asteriti I.A., Rensen W.M., Lindon C., Lavia P., Guarguaglini G. The Aurora-A/TPX2 complex: a novel oncogenic holoenzyme?. Biochim. Biophys. Acta 2010, 1806:230-239.
4. Aytekin T., Ozaslan M., Cengiz B. Deletion mapping of chromosome region 12q13-24 in colorectal cancer. Cancer Genet. Cytogenet. 2010, 201:32-38.
5. Bayliss R., Sardon T., Vernos I., Conti E. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol. Cell. 2003, 12:851-862.
6. Bukau B., Weissman J., Horwich A. Molecular chaperones and protein quality control. Cell 2006, 125:443-451.
7. Cheung C.H., Coumar M.S., Chang J.Y., Hsieh H.P. Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10). Expert Opin. Ther. Pat. 2011, 21:857-884.
8. Chowdhury A., Chowdhury S., Tsai M.Y. A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines. Leuk. Lymphoma. 2012, 53:462-471.
9. Dar A.A., Belkhiri A., Ecsedy J., Zaika A., El-Rifai W. Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res. 2008, 68:8998-9004.
10. Dar A.A., Goff L.W., Majid S., Berlin J., El-Rifai W. Aurora kinase inhibitors-rising stars in cancer therapeutics?. Mol. Cancer Ther. 2010, 9:268-278.
11. Daugaard M., Rohde M., Jaattela M. The heat shock protein 70 family: highly homologous proteins with overlapping and distinct functions. FEBS Lett. 2007, 581:3702-3710.
12. Dutertre S., Prigent C. Aurora-A overexpression leads to override of the microtubule-kinetochore attachment checkpoint. Mol. Interv. 2003, 3:127-130.
13. Evans R., Naber C., Steffler T., Checkland T., Keats J., Maxwell C., Perry T., Chau H., Belch A., Pilarski L., Reiman T. Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells. Leuk. Lymphoma. 2008, 49:559-569.
14. Florin L., Becker K.A., Sapp C., Lambert C., Sirma H., Muller M., Streeck R.E., Sapp M. Nuclear translocation of papillomavirus minor capsid protein L2 requires Hsc70. J. Virol. 2004, 78:5546-5553.
15. Gautschi O., Heighway J., Mack P.C., Purnell P.R., Lara P.N., Gandara D.R. Aurora kinases as anticancer drug targets. Clin. Cancer Res. 2008, 14:1639-1648.
16. Gibbs G.M., Roelants K., O'Bryan M.K. The CAP superfamily: cysteine-rich secretory proteins, antigen 5, and pathogenesis-related 1 proteins-roles in reproduction, cancer, and immune defense. Endocr. Rev. 2008, 29:865-897.
17. Giubettini M., Asteriti I.A., Scrofani J., De Luca M., Lindon C., Lavia P., Guarguaglini G. Control of Aurora-A stability through interaction with TPX2. J. Cell. Sci. 2011, 124:113-122.
18. Gunther M., Laithier M., Brison O. A set of proteins interacting with transcription factor Sp1 identified in a two-hybrid screening. Mol. Cell. Biochem. 2000, 210:131-142.
19. Jiang Y., Zhang Y., Lees E., Seghezzi W. Aurora A overexpression overrides the mitotic spindle checkpoint triggered by nocodazole, a microtubule destabilizer. Oncogene 2003, 22:8293-8301.
20. Kelly K.R., Ecsedy J., Mahalingam D., Nawrocki S.T., Padmanabhan S., Giles F.J., Carew J.S. Targeting aurora kinases in cancer treatment. Curr. Drug Targets 2011, 12:2067-2078.
21. Khalil A.A., Kabapy N.F., Deraz S.F., Smith C. Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets?. Biochim. Biophys. Acta 2011, 1816:89-104.
22. Kim S., Park Y., Park E.S., Cho J.Y., Izzo J.G., Zhang D., Kim S., Lee J.H., Bhutani M.S., Swisher S.G., Wu X., Coombes K.R., Maru D., Wang K.K., Buttar N.S., Ajani J.A., Lee J. Prognostic biokarmers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One 2010, 5:e15074.
23. Li L., Abdel Fattah E., Cao G., Ren C., Yang G., Goltsov A.A., Chinault A.C., Cai W.W., Timme T.L., Thompson T.C. Glioma pathogenesis-related protein 1 exerts tumor suppressor activities through proapoptotic reactive oxygen species-c-Jun-NH2 kinase signaling. Cancer Res. 2008, 68:434-443.
24. Li L., Ren C., Yang G., Fattah E.A., Goltsov A.A., Kim S.M., Lee J.S., Park S., Demayo F.J., Ittmann M.M., Troncoso P., Thompson T.C. GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction. Cancer Res. 2011, 71:7694-7704.
25. McMahon H.T., Boucrot E. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat. Rev. Mol. Cell. Biol. 2011, 12:517-533.
26. Meraldi P., Honda R., Nigg E.A. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. EMBO J. 2002, 21:483-492.
27. Moss D.K., Wilde A., Lane J.D. Dynamic release of nuclear RanGTP triggers TPX2-dependent microtubule assembly during the apoptotic execution phase. J. Cell. Sci. 2009, 122:644-655.
28. Perez Fidalgo J.A., Roda D., Rosello S., Rodriguez-Braun E., Cervantes A. Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system. Clin. Transl. Oncol. 2009, 11:787-798.
29. Portugal J., Mansilla S., Bataller M. Mechanisms of drug-induced mitotic catastrophe in cancer cells. Curr. Pharm. Des. 2010, 16:69-78.
30. Ren C., Li L., Goltsov A.A., Timme T.L., Tahir S.A., Wang J., Garza L., Chinault A.C., Thompson T.C. mRTVP-1, a novel p53 target gene with proapoptotic activities. Mol. Cell. Biol. 2002, 22:3345-3357.
31. Ren C., Li L., Yang G., Timme T.L., Goltsov A., Ren C., Ji X., Addai J., Luo H., Ittmann M.M., Thompson T.C. RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer. Cancer Res. 2004, 64:969-976.
32. Ren C., Ren C.H., Li L., Goltsov A.A., Thompson T.C. Identification and characterization of RTVP1/GLIPR1-like genes, a novel p53 target gene cluster. Genomics 2006, 88:163-172.
33. Rohde M., Daugaard M., Jensen M.H., Helin K., Nylandsted J., Jaattela M. Members of the heat-shock protein 70 family promote cancer cell growth by distinct mechanisms. Genes Dev. 2005, 19:570-582.
34. Saeki T., Ouchi M., Ouchi T. Physiological and oncogenic Aurora-A pathway. Int. J. Biol. Sci. 2009, 5:758-762.
35. Satoh T., Timme T.L., Saika T., Ebara S., Yang G., Wang J., Ren C., Kusaka N., Mouraviev V., Thompson T.C. Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. Hum. Gene Ther. 2003, 14:91-101.
36. Scharer C.D., Laycock N., Osunkoya A.O., Logani S., McDonald J.F., Benigno B.B., Moreno C.S. Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. J. Transl Med. 2008, 6:79.
37. Shiota M., Kusakabe H., Izumi Y., Hikita Y., Nakao T., Funae Y., Miura K., Iwao H. Heat shock cognate protein 70 is essential for Akt signaling in endothelial function. Arterioscler Thromb. Vasc. Biol. 2010, 30:491-497.
38. Singh R., George J., Shukla Y. Role of senescence and mitotic catastrophe in cancer therapy. Cell Div 2010, 5:4.
39. Sonpavde G., Thompson T.C., Jain R.K., Ayala G.E., Kurosaka S., Edamura K., Tabata K., Ren C., Goltsov A.A., Mims M.P., Hayes T.G., Ittmann M.M., Wheeler T.M., Gee A., Miles B.J., Kadmon D. GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin. Cancer Res. 2011, 17:7174-7182.
40. Sumi K., Tago K., Kasahara T., Funakoshi-Tago M. Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells. FEBS Lett. 2011, 585:1884-1890.
41. Tam M., Lin P., Hu P., Lennon P.A. Examining Hedgehog pathway genes GLI3, SHH, and PTCH1 and the p53 target GLIPR1/GLIPR1L1/GLIPR1L2 gene cluster using fluorescence in situ hybridization uncovers GLIPR1/GLIPR1L1/GLIPR1L2 deletion in 9% of patients with multiple myeloma. J. Assoc. Genet. Technol. 2010, 36:111-114.
42. Tsai M.Y., Wiese C., Cao K., Martin O., Donovan P., Ruderman J., Prigent C., Zheng Y. A Ran signalling pathway mediated by the mitotic kinase Aurora A in spindle assembly. Nat. Cell. Biol. 2003, 5:242-248.
43. Vader G., Lens S.M. The Aurora kinase family in cell division and cancer. Biochim. Biophys. Acta 2008, 1786:60-72.
44. Vakifahmetoglu H., Olsson M., Zhivotovsky B. Death through a tragedy: mitotic catastrophe. Cell. Death Differ. 2008, 15:1153-1162.
45. Warner S.L., Stephens B.J., Nwokenkwo S., Hostetter G., Sugeng A., Hidalgo M., Trent J.M., Han H., Von Hoff D.D. Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells. Clin. Cancer Res. 2009, 15:6519-6528.
46. Xiao Y.H., Li X.H., Tan T., Liang T., Yi H., Li M.Y., Zeng G.Q., Wan X.X., Qu J.Q., He Q.Y., Li J.H., Chen Y., Xiao Z.Q. Identification of GLIPR1 tumor suppressor as methylation-silenced gene in acute myeloid leukemia by microarray analysis. J. Cancer Res. Clin. Oncol. 2011, 137:1831-1840.
47. Zhang L., Huang H., Deng L., Chu M., Xu L., Fu J., Zhu Y., Zhang X., Liu S., Zhou Z., Wang Y. TPX2 in malignantly transformed human bronchial epithelial cells by anti-benzo[a]pyrene-7,8-diol-9,10-epoxide. Toxicology 2008, 252:49-55.